Jury verdict leaves Cytek (NASDAQ: CTKB) facing multi-million patent hit
Rhea-AI Filing Summary
Cytek Biosciences, Inc. (CTKB) reported that a jury in the U.S. District Court for the District of Delaware returned a verdict in the patent infringement case brought by Beckman Coulter, Inc. The jury decided in Cytek’s favor on three of the four asserted patent claims, finding both noninfringement and invalidity for those three claims.
For the remaining claim, the jury found no literal infringement but did find infringement under the doctrine of equivalents, and awarded past damages of $20 million in lost profits and $36.11 million in royalties. Cytek stated that the verdict does not require any changes to its current product offerings or operations, and its spectral flow cytometry products remain available globally.
Cytek intends to file post-verdict motions challenging the doctrine-of-equivalents finding and the associated damages, and may pursue other post-trial remedies, including a possible appeal to the U.S. Court of Appeals for the Federal Circuit. The company also highlighted that additional costs, potential injunctive relief, or ongoing royalty obligations could result from further legal proceedings.
Positive
- Jury found in Cytek’s favor on three of four asserted patent claims, including findings of noninfringement and invalidity.
- The verdict does not require changes to Cytek’s current product offerings or operations; its spectral flow cytometry products remain available worldwide.
Negative
- Jury found infringement under the doctrine of equivalents on one claim and awarded past damages of $20 million in lost profits and $36.11 million in royalties.
- Cytek faces ongoing litigation uncertainty, including possible additional costs, injunctive relief, or ongoing royalty obligations depending on post-trial motions and appeals.
8-K Event Classification
3 items: 7.01, 8.01, 9.01
3 items
Item 7.01
Regulation FD Disclosure
Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 8.01
Other Events
Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Key Figures
Number of asserted patent claims: 4 claims
Claims found in Cytek’s favor: 3 claims
Lost profits damages: $20 million
+2 more
5 metrics
Number of asserted patent claims
4 claims
Patent infringement action brought by Beckman Coulter, Inc.
Claims found in Cytek’s favor
3 claims
Jury found noninfringement and invalidity on three of four asserted claims
Lost profits damages
$20 million
Past damages awarded on one claim found infringed under the doctrine of equivalents
Royalty damages
$36.11 million
Past royalties awarded on the same claim
Total past damages
$56.11 million
Sum of lost profits and royalty damages awarded by the jury
Key Terms
doctrine of equivalents, lost profits, royalties, spectral flow cytometry, +1 more
5 terms
doctrine of equivalents legal
"the jury found no literal infringement but found infringement under the doctrine of equivalents"
A patent-law principle that lets a court find infringement even when an accused product or process does not literally match the words of a patent's claims, if it performs substantially the same function in substantially the same way to achieve the same result. Like a different-shaped key that opens the same lock, it can extend a patent's practical coverage beyond its exact wording, and it matters to investors because it affects the scope of legal risk, potential damages, and the value or freedom to use technologies.
lost profits financial
"The jury awarded past damages consisting of $20 million in lost profits"
Lost profits are a legal measure of the earnings a business or individual would have made but for another party’s wrongful act, breach of contract, or interference. Courts or arbitrators estimate those foregone revenues and award damages to restore the injured party to the financial position they would have occupied; for investors, lost-profits claims can affect company liabilities, litigation risk, and reported contingent obligations. Think of it as paying for the income a business can prove it missed out on because of someone else’s actions.
royalties financial
"The jury awarded past damages consisting of $20 million in lost profits and $36.11 million in royalties"
Payments made to the owner of an asset or intellectual property each time that asset is used or a product is sold, often calculated as a percentage of sales or a set amount per unit. Royalties matter to investors because they create predictable, ongoing income streams and affect a company’s cash flow and valuation—like a landlord collecting rent or an author getting a steady cut whenever a book is sold.
spectral flow cytometry technical
"Cytek’s spectral flow cytometry products remain available to customers worldwide"
Spectral flow cytometry is a laboratory technique that analyzes individual cells or particles by capturing the full rainbow of light they emit when tagged with fluorescent markers, rather than measuring a few colors separately. For investors, it matters because it yields more accurate, detailed cell profiles—like upgrading from a limited-color photo to a high-resolution image—helping companies develop better diagnostics, targeted therapies, and faster drug-development decisions.
Full Spectrum Profiling technical
"Cytek independently developed a fundamentally different approach when it pioneered Full Spectrum Profiling technology"
Full spectrum profiling is a comprehensive analysis that measures many types of biological signals—such as genes, proteins, metabolites and other markers—across a sample to build a broad, detailed molecular picture. For investors, it matters because that wide-ranging view can uncover new drug targets, improve predictions of which therapies will work, and support products that personalize care, much like scanning an entire toolbox instead of checking a single tool.
FAQ
What was the outcome of the Beckman Coulter litigation for Cytek Biosciences (CTKB)?
A jury found in Cytek’s favor on three of four asserted patent claims, holding those claims noninfringed and invalid. On the remaining claim, the jury found infringement under the doctrine of equivalents and awarded past damages in lost profits and royalties.
How much in damages was awarded against Cytek Biosciences (CTKB)?
The jury awarded past damages totaling $56.11 million, consisting of $20 million in lost profits and $36.11 million in royalties related to one patent claim found infringed under the doctrine of equivalents.
Will the jury verdict affect Cytek Biosciences’ (CTKB) current products or operations?
Cytek stated that the verdict does not require any changes to its current product offerings or operations. Its spectral flow cytometry products, based on its Full Spectrum Profiling platform, remain available to customers worldwide.
What legal steps does Cytek Biosciences (CTKB) plan after the verdict?
Cytek intends to pursue post-verdict motions challenging the doctrine-of-equivalents finding and damages, and may seek other remedies, including a potential appeal to the U.S. Court of Appeals for the Federal Circuit.
What technology platform is central to Cytek Biosciences’ (CTKB) products?
Cytek’s products are based on its patented Full Spectrum Profiling (FSP) technology, which uses the entire spectrum of fluorescent signals to enable high-resolution, high-content, and high-sensitivity cell analysis with higher multiplexing.
AI-generated analysis. How Rhea-AI works. Not financial advice.
